Recombinant human interleukin-2 injection

This product is a lymphokine that can proliferate cytotoxic T cells, natural killer cells and lymphokine-activated killer cells and enhance their killing activity. It can also promote lymphocytes to secrete antibodies and interferon, and has the effect of promoting the body's immune response.

Main ingredients: recombinant human interleukin-2.

Transparent liquid, no insoluble matter visible to the naked eye.

This product is an anti-tumor biological therapeutic drug, mainly used for the treatment of renal cancer, malignant melanoma and cancerous pleural and abdominal effusions. It can also be used for the comprehensive treatment of other malignant tumors.

For cancer treatment, it can be intravenously infused or subcutaneously injected at a daily dose of 200,000-400,000 IU/m2 of body surface area (500,000-1,000,000 IU/time), once a day, for five consecutive days a week, and a course of treatment of four weeks. For intracavitary injection of cancerous pleural and abdominal effusions, the pleural and abdominal effusions should be drained as much as possible, and each injection should be 400,000-600,000 IU/m2 of body surface area (500,000-1,000,000 IU/time), 1-2 times a week, for 2-4 weeks, or used according to the doctor's instructions based on the patient's condition.

The most common adverse reactions are fever, chills, and muscle aches, which are related to the dosage. Generally, it is a transient fever (about 38°C), and there may also be chills and high fever. The body temperature can return to normal 3 to 4 hours after stopping the drug. Some patients may experience nausea, vomiting, rash, and cold-like symptoms. Subcutaneous injections may cause local redness, swelling, nodules, and pain. All side effects can recover on their own after stopping the drug. When used in larger doses, this product may cause capillary leak syndrome, manifested as hypotension, peripheral edema, temporary renal insufficiency, etc. It should be discontinued immediately and actively treated symptomatically. It should be noted that the safe dosage should be strictly controlled when using this product.

1. Patients with a history of allergy to the ingredients of this product. 2. Patients with high fever, severe heart disease, hypotension, severe heart and kidney insufficiency, abnormal lung function or those who have undergone organ transplantation. 3. Recombinant human interleukin-2, or patients with toxic reactions related to it in the past medication history: ⑴ Sustained ventricular tachycardia; ⑵ Uncontrolled arrhythmia; ⑶ Chest pain accompanied by ECG changes, angina pectoris or myocardial infarction; ⑷ Cardiac tamponade; ⑸ Renal failure requiring dialysis for >72 hours; ⑹ Coma or toxic psychosis for >48 hours; ⑺ Intractable or refractory epilepsy; ⑻ Intestinal ischemia or perforation; ⑼ Gastrointestinal bleeding requiring surgical operation;

Precautions for children: The safety and efficacy of the drug for children under 18 years of age have not been confirmed. Precautions for pregnancy and lactation: There is a lack of adequate controlled research data on this product for pregnant women. This product can only be used when the benefits of using this product outweigh the risks that the fetus may bear. It is not clear whether this product is secreted in human milk. Because this product has potential adverse reactions to infants, the decision to stop breastfeeding or stop taking the drug depends on the importance of the drug to the mother. Precautions for the elderly: The situation that occurs with this product in elderly patients and young patients is the same.

Not yet clear

Store at 2-8℃ away from light.

500,000 IU/0.4ml/vial

24 months

Beijing Four Rings Bio-Pharmaceutical Co., Ltd.

• Founded in:

  1988-10-08

• Address:

  No. 5 Jian'an Street, Beijing Economic and Technological Development Zone, Beijing

• Tax NO.:

  91110302101942400P

• Registered Funds:

  350.92759 million yuan

• Website:

  Log in to view

• Email:

  Log in to view